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Research Article
Melanocortin 1 Receptor Targeted Imaging
of Melanoma With Gold Nanocages
and Positron Emission Tomography
Yongfeng Zhao, PhD1,2, Bo Pang, PhD3, Lisa Detering, MS1,
Hannah Luehmann, MS1, Miaoxin Yang, PhD3, Kvar Black, PhD1,
Deborah Sultan, BS1, Younan Xia, PhD3, and Yongjian Liu, PhD1
Abstract
Purpose: Melanoma is a lethal skin cancer with unmet clinical needs for targeted imaging and therapy. Nanoscale materials
conjugated with targeting components have shown great potential to improve tumor delivery efficiency while minimizing
undesirable side effects in vivo. Herein, we proposed to develop targeted nanoparticles for melanoma theranostics.
Method: In this work, gold nanocages (AuNCs) were conjugated with a-melanocyte-stimulating hormone (a-MSH) peptide and
radiolabeled with 64Cu for melanocortin 1 receptor-(MC1R) targeted positron emission tomography (PET) in a mouse B16/F10
melanoma model.
Results: Their controlled synthesis and surface chemistry enabled well-defined structure and radiolabeling efficiency. In vivo
pharmacokinetic evaluation demonstrated comparable organ distribution between the targeted and nontargeted AuNCs.
However, micro-PET/computed tomography (CT) imaging demonstrated specific and improved tumor accumulation via MC1R-
mediated delivery. By increasing the coverage density of a-MSH peptide on AuNCs, the tumor delivery efficiency was improved.
Conclusion: The controlled synthesis, sensitive PET imaging, and optimal tumor targeting suggested the potential of targeted
AuNCs for melanoma theranostics.
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Introduction
Skin cancer is the fifth most common cancer in the United
States.1 Of various dermatologic malignancies, melanoma
accounts for only 1% of all the incidence but approximately
75% of the death in the case of skin cancer.2 With the
improvement in treatment strategies, malignant melanoma
can be effectively treated upon early detection. However, the
prognosis upon onset of metastasis is poor, as reflected by a
5-year survival rate of only 13% once distant malignancy has
occurred.3 Thus, early and sensitive detection of melanoma is
of paramount importance in improving prognosis and patient
survival. In addition, malignant melanoma is extraordinarily
resistant to chemotherapy, immunotherapy, and external
beam radiation therapy. Thus, new therapeutics are urgently
needed for melanoma.
Nanoparticles, due to the size-promoted enhanced perme-
ability and retention effect in leaky tumor vasculature, have
been widely used for cancer imaging and therapy. Moreover,
the high surface area to volume ratio of nanoparticles also
enables the conjugation of targeting ligands, loading/encapsu-
lation of therapeutic payloads, and labeling of diagnostic ele-
ments. Nanoparticles have been widely studied as multivalent
platforms for cancer theranostics.4-6 Of them, the gold
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nanoparticles with photothermal capability hold great promise
as a theranostic platform for image-guided cancer therapy.7-11
In our previous studies, we have examined the pharmacoki-
netics, tumor targeting, and intratumoral distribution of a vari-
ety of gold nanostructures with different sizes and shapes.12-15
Gold nanocage (AuNCs), due to their efficient photothermal
conversion and favorable biodistribution, are a unique type of
nanostructure for targeted cancer nanomedicine.12,13,15,16
Among the various targets assessed in melanoma detection,
melanocortin 1 receptor (MC1R) has been widely studied due
to its critical role in the incidence and progression of mela-
noma, making it a valid biomarker for the diagnosis of not only
primary tumors but also metastasis in distant organs.17,18 By
conjugating [Nle4, D-Phe7]-a-melanocyte-stimulating hor-
mone (NDP-a-MSH), Lu et al have demonstrated receptor-
mediated active targeting and efficient photothermal ablation
of melanoma with gold nanoshells in a murine tumor model.19
However, the imaging potential of these targeted
nanostructures for melanoma has not been fully realized as a
reference to guide the treatment. Previously, we studied the
photoacoustic imaging of melanoma using NDP-a-MSH-
conjugated AuNCs (ca 60 nm in size) in a mouse B16 model
showing sensitive and specific detection of tumors.20 However,
the pharmacokinetics and tumor targeting efficiency of AuNCs
need further optimization to enhance its theranostic potential.
Herein, we prepared AuNCs of approximately 40 nm in size
for MC1R-targeted imaging in a mouse B16/F10 melanoma
model. Through 64Cu radiolabeling, we examined the organ
distribution profile of AuNCs and compared the tumor imaging





mide (OPSS-PEG-SVA, MW  5000) and poly(ethylene gly-
col)monomethyl ether thiol (MW  5000) were both obtained
from Laysan Bio (Arab, Alabama). S-2-(4-Aminobenzyl)-
1,4,7,10-tetraazacyclododecane tetraacetic acid (NH2-Bn-
DOTA) was purchased from Macrocyclics (Dallas, Texas).
[Nle4, D-Phe7-Lys(Dde)]-a-MSH [NDP-MSH (Dde)-a-NH2]
peptide was customized by CPC Scientific (Sunnyvale, Cali-
fornia). Other chemicals and reagents, including poly(vinylpyr-
rolidone) (PVP, MW  55 000), gold (III) chloride trihydrate
(HAuCl4.3H2O), ascorbic acid, sodium chloride (NaCl), and
phosphate-buffered saline (PBS) were obtained from Sigma-
Aldrich (St. Louis, Missouri). All chemicals were used as
received unless specified.
Synthesis of Gold Nanocages
Gold nanocages covered with PVP were prepared using a
galvanic replacement reaction between Ag nanocubes and
HAuCl4 following a previously reported protocol.
21 The
reaction was frequently monitored by measuring the localized
surface plasmon resonance (LSPR) peaks with UV-Vis
spectroscopy (Cary 50 spectrometer, Varian, Palo Alto,
California) during the reaction. The reaction was stopped when
the LSPR reached approximately 800 nm. After washing with
saturated NaCl solution, the AuNCs were collected by centri-
fugation at 15 000g for 15 minutes, and purified by washing
with MilliQ water 3 times.
Preparation of OPPS-PEG-MSH
The OPSS-PEG-MSH molecule was prepared by coupling the
primary amine group on the NDP-a-MSH peptide to OPSS-
PEG-SVA (Figure 1). The amine-reactive OPSS-PEG-SVA
was mixed with NDP-a-MSH (Dde)-NH2 peptide in PBS (pH
7.4) at a molar ratio of 1:5 and allowed to react at 4C over-
night. The solution containing the OPSS-PEG-MSH(Dde) con-
jugate was desalted with a centrifuge filter (Amicon, 3 kDa)
and washed with MilliQ water. The concentrated solution was
recovered and lyophilized. The resulting solid was added to 2%
hydrazine in N,N-dimethylformamide (DMF).19 After 1 hour
incubation at room temperature, the OPPS-PEG-MSH was pre-
cipitated by adding diethyl ether and collected by centrifuga-
tion at 22 000g for 5 minutes. The supernatant was removed,
and the remaining pellet was washed with diethyl ether. The
pellet was further dried by air and stored at 20C for future
use.
Preparation of OPPS-PEG-DOTA
The OPSS-PEG-DOTAmolecule was prepared by coupling the
primary amine group on DOTA-NH2 with OPSS-PEG-SVA.
The amine-reactive OPSS-PEG-SVA was mixed with DOTA-
NH2 in pH 7.4 PBS buffer at a molar ratio of 1:5 and allowed to
react at 4C overnight. The solution containing the OPSS-PEG-
DOTA was desalted with a centrifuge filter (Amicon, 3 kDa)
and washed with MilliQ water.
Conjugation of PEG, PEG-DOTA, and PEG-MSH to
AuNCs
The MSH peptide conjugated AuNCs (MSH-PEG-AuNCs)
were prepared by adding AuNCs solution to a mixture of
OPSS-PEG-MSH, OPPS-PEG-DOTA, and HS-PEG-OMe
(MW  5000; OPSS-PEG-MSH:OPPS-PEG-DOTA:HS-
PEG-OMe ¼ 1:4:4) with a total PEG to AuNCs molar ratio
of 105 to 1 (Figure 1). The mixture was allowed to incubate
at 4C overnight on a shaker. The conjugated AuNCs were
purified by centrifugation at 11 000g for 15 minutes. The
pellet was redispersed in MilliQ water and centrifuged
again. For AuNCs conjugated with a high density of MSH,
the same conjugation strategy was used but with an elevated




Comparison of Photothermal Effects of Nontargeted
AuNCs-PEG and Targeted AuNCs-PEG-MSH
Aqueous suspensions of the nontargeted AuNCs-PEG and tar-
geted AuNCs-PEG-MSH at identical concentrations were
placed on a 96-well plate and irradiated with a diode laser
(l¼ 808 nm, Power Technology, Alexander, Arkansas) directly
from above at a power density of 1.1 W/cm2. The temperature
changes were monitored using a NIR camera (ICI7320, Infrared
Camera, Beaumont, Texas) placed on top of the suspension at 6-
second intervals. The average temperature of the suspension was
determined from the thermograph using IR Flash software
(Infrared Camera, version 2.10) at each time point.
Radiolabeling of AuNCs-PEG-MSH and AuNCs-PEG
64Cu (t1/2¼ 12.7 h, bþ ¼17%, b ¼ 40%) was produced on the
Washington University Medical School CS-15 cyclotron by the
64Ni (p, n) 64Cu nuclear reaction. AuNCs-PEG-MSH or
AuNCs-PEG (about 6 pmol) were incubated with 185 MBq
64Cu2þ in 0.1 M ammonium acetate buffer (pH 5.5) at 45C
for 1 hour to achieve maximal labeling-specific activity. The
64Cu-AuNCs-PEG-MSH or 64Cu-AuNCs-PEG were dissolved
in MilliQ water and purified by centrifugation at 15 000g for
15 minutes followed by filtration through a 0.22 mmol/L
syringe filter. After ethylenediaminetetraacetic acid (EDTA,
10 mmol/L in 50 mmol/L pH 7.4 phosphate buffer) challenge,
the radiochemical purity of radiolabeled AuNCs was measured
by radio instant thin layer chromatography (radio-iTLC,
Bioscan, Washington, DC).
Biodistribution of 64Cu-AuNCs-PEG-MSH or
64Cu-AuNCs-PEG
All animal studies were performed in compliance with guide-
lines set forth by the NIH Office of Laboratory Animal Welfare
and approved by the Washington University Animal Studies
Committee. Biodistribution studies were performed in male
C57BL/6 mice weighing 20 to 25 g (n ¼ 4, Charles River
Laboratory, Wilmington, Massachusetts) with 0.37 MBq
(0.057 pmol) of 64Cu-AuNCs-PEG-MSH or 64Cu-AuNCs-
PEG in 100 mL of saline (APP Pharmaceuticals, Schaumburg,
Illinios) injected via the tail vein. The mice were anesthetized
Figure 1. Scheme for the preparation of AuNC-PEG-MSH.
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with inhaled isoflurane during tracer injection and reanesthe-
tized before euthanasia by cervical dislocation at each time
point. Organs of interest were collected, weighed, and counted
with a Beckman 8000 gamma counter (Beckman, Brea, Cali-
fornia). Standards were prepared and measured along with the
samples to calculate the percentage of the injected dose per
gram of tissue (%ID/g).10,22
Positron Emission Tomography/Computed Tomography
of 64Cu-AuNCs-PEG-MSH
The B16/F10 cell line was obtained from the American Type
Culture Collection (ATCC, Manassas, Virginia). The cells
were cultured in Dulbecco’s Modified Eagle’s medium supple-
mented with 10% fetal bovine serum and 1% penicillin/strep-
tomycin and incubated at 37C in a humidified atmosphere of
5% CO2. Ten days after 5 105 B16/F10 cells were implanted,
nude mice were anesthetized with isoflurane and injected with
3.7 MBq (0.57 pmol) of 64Cu-AuNCs-PEG-MSH in 100 mL of
saline via the tail vein. MicroPET scans were performed on
either microPET Focus 220 (Siemens, Malvern, Pennslyvania)
or Inveon PET/CT system (Siemens) at 4, 24, and 48 hours
postinjection. The competitive receptor blocking study was
performed by coinjection of nonradiolabeled AuNCs-PEG-
MSH and 64Cu-AuNCs-PEG-MSH with a molar ratio of
35:1. The PET images were corrected for attenuation, scatter,
normalization, and camera dead time and coregistered with CT
images. Both PET scanners were cross-calibrated periodically.
The PET images were reconstructed with the maximum a pos-
teriori (MAP) algorithm and analyzed by ASIPro (Siemens
Medical solutions, Knoxville, Tennessee). The tumor uptake
of the radiolabeled AuNCs was calculated as %ID/g in
3-dimensional regions of interest.
Histology and Immunohistochemistry
Sections of tumor in 5 mm thickness were cut from
paraformaldehyde-fixed (24 hours), paraffin-embedded speci-
mens. The sections were deparaffinized and rehydrated through
a series of xylenes and graded alcohols before undergoing anti-
gen retrieval pretreatment (10 mmol/L Tris, 1 mmol/L EDTA,
0.05% Tween, pH 9.0, for 10 minutes). They were treated with
0.3% H2O2 for 30 minutes, followed by blocking serum for 1
hour to prevent nonspecific binding (Vectastain, Vector
Laboratories, Burlingame, California). The sections were then
incubated overnight at 4C with primary antibody (anti-
melanin, 1:100 in blocking serum, Santa Cruz Biotechnology,
Dallas, Texas). Secondary antibody was applied (Vector
Laboratories), and blue color development was achieved using
an alkaline phosphatase-based immunostaining kit (Vector
Laboratories).
Statistical Analysis
Group variation is described as the mean (standard deviation).
Group comparisons were made using the student t test. The
significance level in all tests was P  .05. GraphPad Prism
v. 6.04 (La Jolla, California) was used for all statistical
analyses.
Results and Discussion
Synthesis and Characterization of AuNCs-PEG-MSH
Previously, we used 50-nm AuNCs conjugated with [Nle4,
D-Phe7]-a-melanocyte-stimulating hormone (NDP-a-MSH)
peptide for melanoma photoacoustic imaging and showed
sensitive and specific detection of MC1R in a mouse B16
model.20 However, the large size of AuNCs led to unfavorable
in vivo pharmacokinetics and high uptake by the mononuclear
phagocyte system (MPS: liver, and spleen). Thus, we pre-
pared MC1R-targeted AuNCs-PEG-MSH using AuNCs with
an edge length of 35 nm and a wall thickness of 3.6 nm
(Figure 2A) by following the procedure outlined in Figure
1. Due to the well-defined structure and inherent optical prop-
erties of AuNCs, the surface modification did not change the
LSPR peak of the AuNCs, which was illustrated by the almost
identical LSPR peaks around 790 nm for the unmodified
AuNCs, AuNCs-PEG, and AuNCs-PEG-MSH shown in Fig-
ure 2B.20 Moreover, as shown in Figure 2C, the 3 samples of
nanocages also displayed comparable efficiencies for the
photothermal effect to convert light to heat, suggesting no
aggregation during PEGylation.19 Following our previous
strategy for quantifying the PEGylation density,13 the number
of NDP-a-MSH peptides conjugated with the AuNCs was
estimated to be approximately 1800 copies per AuNC. These
nanocages were then efficiently radiolabeled with 64Cu2þ
through the DOTA chelator conjugated with the AuNCs,
enabling high-specific activity (6.5 MBq/pmol) and trace
amount (0.057 and 0.57 pmol for biodistribution and PET
imaging, respectively) administration for in vivo applications.
After centrifugal purification, the radiochemical purity of
64Cu-AuNCs-PEG-MSH (> 95% pure) was confirmed by
radio-iTLC (Figure 2D) prior to intravenous injection.
Biodistribution of AuNCs-PEG-MSH
Biodistribution studies of the purified 64Cu-AuNCs-PEG-
MSH and 64Cu-AuNCs-PEG were conducted in wild-type
C57BL/6 mice at 4 and 24 hours postinjection. As shown in
Figure 3, the targeted and nontargeted nanocages showed
comparable in vivo organ distribution profiles at the 2 time
points. Both nanocages showed high blood retentions around
20% ID/g (20.30 + 1.84%ID/g for 64Cu-AuNCs-PEG and
19.89 + 2.52%ID/g for 64Cu-AuNCs-PEG-MSH) at 4 hours,
followed by rapid decrease to less than 2%ID/g at 24 hours,
which was also verified by the variations in other blood pool
organs including heart and lungs. The high blood retention of
both targeted and nontargeted nanocages indicates high effi-
ciency of surface modification and is consistent with our pre-
vious study for nontargeted nanocages.13 Although the uptake
in MPS system was at least 2 times less than their bigger
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counterpart,13 due to the heavy metal nature and sizes,23,24
both nanocages still had significant liver and spleen accumu-
lation but slightly different patterns. In contrast to the slightly
increased liver accumulations (12.4 + 2.66%ID/g at 4 hours
to 19.2 + 0.91%ID/g at 24 hours) of 64Cu-AuNCs-PEG, the
hepatic uptake of 64Cu-AuNCs-PEG-MSH was relatively sta-
ble during the 24-hour study (15.1+ 3.92%ID/g and 17.6+
1.77%ID/g at 4 hours and 24 hours, respectively). Although
the spleen accumulations of both nanocages were comparable
to those in liver at 4 hours, both significantly increased at 24-
hour time point (86.9 + 10.7%ID/g and 90.3 + 10.9%ID/g
for 64Cu-AuNCs-PEG-MSH and 64Cu-AuNCs-PEG, respec-
tively, P < .0001 for both, n ¼ 4/group), which was also
consistent with our previous report about the size effect of
nanoparticles in spleen accumulation.25,26 Owing to the sim-
ilar in vivo pharmacokinetics of the 2 nanocages, the nontar-
geted 64Cu-AuNCs-PEG could serve as a useful control to
study the tumor targeting effect enabled by the conjugation
of a-MSH peptide.
Positron Emission Tomography/Computed Tomography
Imaging of AuNCs-PEG-MSH
Positron emission tomography/computed tomography images
of 64Cu-AuNCs-PEG-MSH showed tumor accumulation at
24 hours postinjection in a B16/F10 mouse melanoma model
(Figure 4A). The high uptakes in liver and spleen were also
consistent with the biodistribution studies. Quantitative tumor
uptake analysis demonstrated 4.57+ 0.36%ID/g (n¼ 4/group)
accumulation within the tumor, comparable to the results
acquired with targeted gold nanospheres.27 The nontargeted
64Cu-AuNCs-PEG showed weak signals within the tumor, con-
firmed by the significantly lower tumor accumulation (3.40+
0.34%ID/g, P < .001, n ¼ 4/group). Through competitive
receptor blocking, the tumor accumulation of 64Cu-AuNCs-
PEG-MSH was significantly decreased (3.59 + 0.30%ID/g,
P < .001, n ¼ 4/group), showing no statistical difference from
that of 64Cu-AuNCs-PEG, demonstrating the targeting specifi-
city of 64Cu-AuNCs-PEG-MSH. A further analysis of the
Figure 2. Characterization of gold nanocages. A, Transmission electron microscopy image of AuNC-PEG-MSH. B, UV-Vis spectra of unmo-
dified gold nanocages (AuNCs), AuNCs-PEG, and AuNCs-PEG-MSH showing similar LSPR peaks. C, Plots of temperatures as a function of
irradiation time for suspension of H2O, AuNCs, AuNCs-PEG, AuNCs-PEG-MSH. The concentration (0.025 nmol/L) of each suspension had the
same maximum extinction intensity. The laser power density was 1.1 W/cm3. D, Instant radio-thin layer chromatogram (iTLC) of purified
64Cu-AuNCs-PEG-MSH.
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tumor localization showed that the tumor/muscle uptake ratio
of the targeted nanocages was 20.26 + 4.54 (n ¼ 4/group),
twice of that acquired using the nontargeted nanocages (10.11
+ 1.84, P < .001, n ¼ 4/group), indicating the advantage of
targeted AuNCs for cancer diagnosis.
To further improve the targeting efficiency of 64Cu-AuNCs-
PEG-MSH in vivo, the amount of NDP-a-MSH peptide
conjugated with the surface of AuNCs was increased to 5400
copies/AuNC by increasing the molar ratio of OPPS-PEG-
MSH to HS-PEG-OMe during the conjugation reaction. Inter-
estingly, the increased conjugation of targeting NDP-a-MSH
peptide also led to increased uptake in the B16/F10 tumors, as
demonstrated in Figure 5A. The quantitative analysis showed
the tumor localization was 7.43+ 0.55%ID/g (n ¼ 4/group) at
24 hours and remained stable up to 48 hours (7.52+ 0.40%ID/
g, n¼ 4/group). Both were twice as much as that acquired with
nontargeted 64Cu-AuNCs-PEG (P < .001, n ¼ 4/group).
Through the coinjection of nonradiolabeled AuNCs-PEG-
MSH in excess amount, the tumor uptake was significantly
blocked (4.58+ 0.69%ID/g, P < .001, n ¼ 4/group), suggest-
ing the targeting specificity. Additionally, the elevated tumor
uptake also led to improved tumor/muscle contrast ratio, which
were 19.67 + 0.60 at 24 hours (n ¼ 4/group) and further
increased to 30.48 + 1.27 at 48 hours (n ¼ 4/group), which
will help to better localize the tumor for photothermal
treatment and reduce the side effect in the future. Furthermore,
the improved targeting sensitivity and specificity may be
particularly useful for detecting small metastatic lesions in
distant organs such as liver due to the stable background
hepatic accumulation during the 24-hour study.
Currently, there are a lot of effort using combined strategy
for melanoma treatment such as integrating immunotherapy,
BRAF inhibitor, and radiotherapy, which has shown significant
efficacy in patients. However, due to the lack of noninvasive
imaging approach, it is challenging to fulfill the goal of perso-
nalized therapy. The AuNCs developed herein has the potential
to serve as a multivalent platform to integrate the imaging and
therapy together for melanoma theranostics by loading/encap-
sulating small molecule inhibitors, radiolabeling with
67Cu/64Cu for MSH peptide-directed treatment following PET
guidance.28-31
Characterization of MC1R Receptor
Histopathological analysis of B16/F10 tumor and characteriza-
tion of MC1R receptor was also performed in the collected
tumor tissues. As shown in Figure 6, the hematoxylin and eosin
staining showed a high level of large and polynucleated tumor
cells in the B16/F10 tumors collected at 10 days postimplant.
Immunohistochemical staining of the tumor demonstrated the
high expression of MC1R receptor in malignant melanocytes
across the tumor (Figure 6), which is consistent with high tar-
geting effect of 64Cu-AuNCs-PEG-MSH.
Conclusion
In summary, we have demonstrated the synthesis of MSH-
conjugated AuNCs with well-defined structure and surface
chemistry for MC1R-targeted imaging in a mouse B16/F10
melanoma model. The high radiolabeling-specific activity of
AuNCs ensured the trace amount administration for in vivo
applications. Pharmacokinetic evaluation of 64Cu-AuNCs-
PEG-MSH showed high initial blood circulation, followed
by fast clearance for low background. Positron emission
tomography/computed tomography imaging of the MC1R-
targeted 64Cu-AuNCs-PEG-MSH demonstrated sensitive and
specific detection of MC1R in the B16/F10 tumors, confirmed
by the overexpression of MC1R in tumor cells. By increasing
the loading of targeting a-MSH peptide onto the surface of
AuNCs, the tumor targeting efficiency was also increased,
indicating the effectiveness of this targeting strategy in
improving tumor delivery for potential photothermal therapy.
However, there are also some limitations associated with the
current studies. The biodistribution profile of 64Cu-AuNCs-
PEG-MSH needs to be improved to reduce MPS system
accumulation and minimize any potential toxicity concerns.
The targeting efficiency needs to be further enhanced for
future photothermal treatment studies.
Figure 3. In vivo biodistribution of 64Cu-AuNCs-PEG-MSH and 64Cu-
AuNCs-PEG in wild-type C57BL/6 mice at 4 (top panel) and 24 hours
(bottom panel) (n ¼ 4/group) postintravenous injection.
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Figure 5. A, Representative positron emission tomography/computed tomography (PET/CT) images of 64Cu-AuNCs-PEG-MSH with high
loading of a-melanocyte-stimulating hormone (a-MSH) peptide and competitive receptor blocking studies in mice-bearing B16/F10 melanoma at
24 and 48 hours postinjection. The competitive blocking studies were carried with coinjection of non-radiolabeled AuNCs-PEG-MSH con-
jugated with a high loading of a-MSH peptide in excess amount (molar ratio of AuNCs-PEG-MSH: 64Cu-AuNCs-PEG-MSH ¼ 40:1; T, tumor). B,
Quantitative tumor uptake analysis at 24 and 48 hours (n ¼ 4/group). C, Tumor-to-muscle ratio of 64Cu-AuNCs-PEG-MSH with high a-MSH
peptide at 24 and 48 hours (n ¼ 4/group). *P < .005, **P < .001.
Figure 4. A, Representative positron emission tomography/computed tomography (PET/CT) images of 64Cu-AuNCs-PEG-MSH, 64Cu-AuNCs-
PEG, and competitive receptor blocking in mice bearing B16/F10 melanoma at 24 hours postinjection. The blocking study was carried by
coinjection of nonradiolabeled AuNCs-PEG-MSH in excess (molar ratio of AuNCs-PEG-MSH to 64Cu-AuNCs-PEG-MSH at 40:1; yellow Arrow
T, Tumor). B, Quantitative tumor uptakes of 64Cu-AuNCs-PEG-MSH, 64Cu-AuNCs-PEG, and blocking studies at 24 hours. (n ¼ 4/group). C,
Tumor-to-muscle ratio of 64Cu-AuNCs-PEG-MSH and 64Cu-AuNCs-PEG at 24 hours (n ¼ 4 / group). *P < .05, **P < .001.
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